Breast Milk Transfer and Dosing Recommendations
For a 3-month-old preterm infant who is regaining weight, metronidazole should be avoided during breastfeeding, while trimethoprim-sulfamethoxazole (Trax-S) and azithromycin can be used with specific precautions and close infant monitoring.
Drug-Specific Transfer and Safety Profile
Trimethoprim-Sulfamethoxazole (Trax-S)
Yes, it crosses into breast milk but at very low levels. Trimethoprim-sulfamethoxazole is found in breast milk at concentrations an order of magnitude lower than therapeutic infant doses 1.
However, this medication is specifically contraindicated for your situation. 1, 2 explicitly state that TMP-SMX should be avoided in premature infants due to theoretical risk of:
- Bilirubin displacement leading to kernicterus
- Hyperbilirubinemia
- Hemolytic anemia in glucose-6-phosphate dehydrogenase deficient infants
If absolutely necessary with no alternatives: Standard maternal dosing can be used (trimethoprim 320 mg/sulfamethoxazole 1,600 mg daily in 2 divided doses), but the infant requires close monitoring for jaundice and feeding adequacy 1.
Azithromycin
Yes, it crosses into breast milk in small amounts. The relative infant dose is approximately 15.7% of the maternal weight-adjusted dose 3, which exceeds the typical 10% safety threshold but remains in a range where many experts consider short-term use acceptable 2.
Critical timing consideration: There is a very low risk of hypertrophic pyloric stenosis in infants exposed to macrolides during the first 13 days of breastfeeding only (not after 2 weeks) 2.
Maternal dosing: Standard therapeutic doses can be used. The FDA label 4 states azithromycin is excreted in human milk and caution should be exercised, but does not contraindicate breastfeeding.
Monitoring required: Watch the infant for gastrointestinal symptoms, particularly in the first 2 weeks of exposure.
Metronidazole
Yes, it crosses extensively into breast milk. This is the most problematic of the three medications. Metronidazole and its metabolite are excreted at a median absolute infant dose of 1.59 mg/kg/day, equivalent to 10.61% of the therapeutic infant dose 5.
The most recent 2025 guideline explicitly advises against breastfeeding for mothers taking metronidazole 5 due to:
- Relatively high exposure through breast milk
- Unknown effects on infant microbiome and immune system
- Documented instances of diarrhea and increased Candida growth in exposed infants
- FDA concerns about potential tumorigenicity (though this is based on rodent studies) 6
If a short course is absolutely necessary (≤1 week):
- After a single 2g dose: Stop breastfeeding for 12-24 hours 2, 7
- For multiple daily doses (400mg three times daily): Peak milk concentrations occur 2-4 hours post-dose and gradually decrease over 12-24 hours 5
- Close monitoring required for diarrhea, candidiasis (oral/perianal), and gastrointestinal flora disruption
Clinical Algorithm for Your Specific Situation
Given your infant is preterm and only 3 months old while regaining weight, this represents a particularly vulnerable population:
Trimethoprim-Sulfamethoxazole: Avoid if possible. The 2021 CDC guideline 1 and 2020 ERS/TSANZ guideline 2 specifically list prematurity as a contraindication due to bilirubin displacement risk.
Azithromycin: Can be used with caution. Monitor infant closely for pyloric stenosis symptoms (projectile vomiting) if infant is <2 weeks into exposure, and for any gastrointestinal disturbances.
Metronidazole: Should be avoided based on 2025 consensus 5. If absolutely required for maternal health, consider temporary cessation of breastfeeding or pump-and-discard for 12-24 hours after each dose.
Key Monitoring Parameters
For any antibiotic exposure during breastfeeding in your preterm infant:
- Gastrointestinal flora disruption: diarrhea, candidiasis (oral thrush, diaper rash)
- Feeding adequacy: ensure continued weight gain
- Jaundice (particularly with TMP-SMX)
- Allergic reactions: rash, irritability
The vulnerability of your preterm infant who is still regaining weight makes the risk-benefit calculation lean heavily toward avoiding metronidazole and TMP-SMX when safer alternatives exist.